Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells

Click to increase image sizeClick to decrease image size

Authors’ contributions

S.O. and M.M. developed the concept and designed the study. S.O. and A.G. wrote the manuscript. S.O. performed the experiments and assisted in creating figures. The final manuscript has been read and approved by all authors.

Disclosure statement

A.G. received research funding from Eisai Co., Ltd, Ono Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Nippon Shinyaku Co., Ltd, Chugai Pharmaceutical Co., Ltd, MSD K.K., Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Nippon Shinyaku Co., Ltd, Bayer Yakuhin, Ltd, Daiichi Sankyo Co., Ltd, and Nihon Pharmaceutical Co., Ltd. A.G. reports honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd, Ono Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Nippon Shinyaku Co., Ltd, Chugai Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Daiichi Sankyo Co., Ltd, Nihon Pharmaceutical Co., Ltd, Kyowa Kirin Co., Ltd, Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Sanofi K.K. A.G. reports consulting fees from PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd, and Alexion Pharmaceuticals, Inc. A.G. also reports participation in the data safety monitoring board or advisory board of PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd, and Alexion Pharmaceuticals Inc. S.O. and M.M. report there are no competing interest to declare.

Additional information

Funding

The Japanese Ministry of Education, Culture, Sports, Science and Technology provided financial support for this study (20K07644).